

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

G Pérez-Tenorio^{*1}, O Stål¹ and members of the Southeast Sweden Breast Cancer Group²

¹Department of Biomedicine and Surgery, Division of Oncology, Clinical Research Center, Faculty of Health Sciences, Linköping University, SE-581 85 Linköping, Sweden

Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with tyrosine kinase receptors. The protein is a downstream effector of *erbB-2* with implications in breast cancer progression and drug resistance *in vitro*. We aimed to examine the role of Akt-1 in breast cancer patients, by determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The expression of *erbB-2*, heregulin $\beta 1$ and Bcl-2 was also assessed by flow cytometry or immunohistochemistry. This study comprised 93 patients, aged <50 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated with lower S-phase fraction ($P=0.001$) and the presence of heregulin $\beta 1$ -expressing stromal cells ($P=0.017$). Neither Akt-1 nor pAkt was related with other factors. Tumour cells-derived heregulin $\beta 1$ was found mainly in oestrogen receptor negative ($P=0.026$) and node negative ($P=0.005$) cases. Survival analysis revealed that pAkt positive patients were more prone to relapse with distant metastasis, independently of S-phase fraction and nodal status (multivariate analysis; $P=0.004$). The results suggest that activation of Akt may have prognostic relevance in breast cancer.

British Journal of Cancer (2002) 86, 540–545. DOI: 10.1038/sj/bjc/6600126 www.bjcancer.com

© 2002 Cancer Research UK

Keywords: breast cancer; endocrine treatment; Akt; PKB; *erbB-2*; heregulin $\beta 1$

Endocrine therapy remains the most used systemic treatment in breast cancer. The presence of oestrogen receptor (ER) is the guide in the therapeutic decision. Complete oestrogen blockade seems to be more effective compared with single agent endocrine treatment. Combined therapy, involving luteinizing hormone-releasing hormone (LHRH) analogues such as goserelin (Zoladex) and tamoxifen has been employed to reduce oestrogen levels and to prevent the oestrogenic activity at the cellular level (Michaud and Buzdar, 2000). However in spite of higher response rate, tumour resistance to endocrine treatments develops over time and constitutes a critical problem (MacGregor and Jordan, 1998; Clarke *et al*, 2001).

Anti-oestrogen resistance may be explained by several mechanisms, including loss or mutation of ER, increased estradiol level, alterations in anti-oestrogen metabolism or interactions between growth factor receptors and ER cascades (reviewed in Clarke *et al*, 2001). These mechanisms, mainly involved in cell proliferation, may coexist with those affecting cell death. Increasing amount of evidence indicates that the mechanisms whereby drugs such as the LHRH analogues and tamoxifen exert the cytotoxic action also include apoptosis (Perry *et al*, 1995; Imai and Tamaya, 2000). Therefore, factors involved in the apoptotic failure may also contribute to the anti-oestrogen resistance.

Recently, the phosphatidylinositol 3' kinase (PI3K)/Akt cascade, which is the major survival pathway for many cell types, has been

related to activation of ER *in vitro* and with protection from tamoxifen-induced apoptosis (Campbell *et al*, 2001).

Akt, also called protein kinase B (PKB), is the cellular homologue of the vAkt oncogene found in the highly transforming retrovirus AKT8 (Ahmed *et al*, 1993). Human Akt exists as three closely related isoforms: Akt-1/PKB α , Akt-2/PKB β and Akt-3/PKB γ . Akt-1 is activated by phosphorylation on two critical residues: threonine 308 in the kinase domain and serine 473 in the C-terminal tail. The active protein (pAkt) is a downstream effector of the growth factor-stimulated PI3K (Coffer *et al*, 1998) and may contribute to the genesis of cancer by blocking programmed cell death (Kandel and Hay, 1999).

From *in vitro* studies it is known that induction of cell survival by Akt isoforms affects signalling cascades triggered by a wide range of receptors. Platelet-derived growth factor (PDGF) (Klinghoffer *et al*, 1996), insulin growth factor (IGF) (Duan *et al*, 1999), and the epidermal growth factor (EGF) family members (Ram and Ethier, 1996; Okano *et al*, 2000) are among those receptors. Akt-1 has been found in correlation with higher expression of *erbB-2* in a panel of breast cancer cell lines (Ahmad *et al*, 1999). A recent report showed that inhibition of this pathway with a monoclonal antibody against *erbB-2* was not restricted to cells that overexpressed *erbB-2* but also interfered with heregulin $\beta 1$ (HRG)-mediated activation in cells with basal levels of the receptor (Liu *et al*, 1999). The former indicates that both, overexpression of *erbB-2* and stimulation with HRG could be able to trigger this pathway (Tan *et al*, 1999; Ignatoski *et al*, 2000).

Until the present, Akt isoforms has been found overexpressed in several tumour types (Staal, 1987; Bellacosa *et al*, 1995; Cheng *et al*, 1996; Ruggeri *et al*, 1998) but the information in breast cancer is limited. In the present study we analyzed the expression and activation of Akt-1 in relation to some factors involved in its pathway

*Correspondence: G Pérez-Tenorio; E-mail: gizpe@ibk.liu.se

²Members of the Southeast Sweden Breast Cancer Group are listed at the end of this study.

Received 18 May 2001; revised 3 December 2001; accepted 5 December 2001

as well as other tumour characteristics. We also aimed to examine the significance of this protein for patient's survival after endocrine treatment.

MATERIALS AND METHODS

Patients

This study comprised 93 breast cancer patients (35–49 years) from the Southeast Sweden Health Care Region who underwent surgery between 1984 and 1996. All patients were treated with tamoxifen, goserelin or both endocrine modalities. The tumours were positive for ER or progesterone receptor (PgR) in 96% of the cases. The medium follow-up time among the disease-free patients was 64 months. The first relapse appeared 20 months after surgery and further on 22 patients (24%) relapsed with distant metastasis. For this study we used frozen sections from tumours still available after hormone receptor assays. The material was stored at -70°C until used.

Determination of steroid receptors and S-phase fraction

The levels of steroid hormones were measured using the EIA assay from Abbot (Lab. Diagnostic Division, Abbot Park, USA). Samples with ER or PgR ≥ 0.3 fmol μg^{-1} DNA were considered as positive. Likewise, DNA flow cytometry was performed in clinical routine practice to determine the S-phase fraction (SPF). A cut-off level of 10% was used to differentiate tumours with low and high SPF respectively. Both methods have been described previously (Stål *et al*, 1992).

Flow cytometry to determine *erbB-2* content

This method was previously described (Stål *et al*, 1994). Fixation was carried out in 1% paraformaldehyde for 3 min. The cells were incubated with the monoclonal antibody *c-neu* (Ab-2), clone 9G6 (Oncogene Science Inc., Manhasset, NY, USA) or an irrelevant isotype control antibody (Sigma Chemical Co., St Louis, MI, USA), both diluted in PAB at $1 \mu\text{g ml}^{-1}$. The secondary antibody rabbit-anti-mouse F(ab)₂ conjugated with FITC (DAKO, Denmark) was added at a 1:50 dilution. Finally the cells were treated with RNase, stained with propidium iodide and analyzed in a FACScan flow cytometer (Becton Dickinson, USA). A fluorescence index (FI) was calculated as the ratio between the geometrical mean of the fluorescence associated with the specific antibody and the negative control. Tumours with FI ≥ 2.0 were considered as positive.

Immunohistochemical detection

The staining procedure followed a standard protocol. Imprints from nine tumours, otherwise frozen-sections (5 mm) were used for this purpose. Slides were fixed in acetone for 10 min at 4°C ; blocked in PBS-10% swine serum (DAKO, Denmark) and incubated with the primary antibodies: a mouse monoclonal antibody, clone 124 ($3.5 \mu\text{g ml}^{-1}$) (DAKO, Denmark) to detect Bcl-2; a sheep polyclonal antibody (at $8 \mu\text{g ml}^{-1}$) against the phosphorylated Ser residue in position 473 of human Akt-1 (Upstate Biotechnology; Lake Placid, NY, USA); and goat polyclonal antibodies against-HRG (at $0.5 \mu\text{g ml}^{-1}$) and Akt-1 (at $8 \mu\text{g ml}^{-1}$) respectively (Santa Cruz Biotechnology, Inc). The negative control, in case of Bcl-2, consisted of a mouse IgG1 kappa-Mopc 21 (Sigma Aldrich, Sweden) at a concentration of $8 \mu\text{g ml}^{-1}$ while the polyclonal antibodies were incubated with their respective neutralizing peptides. Incubation with primary antibodies was performed overnight at 4°C in a moisture chamber. As secondary antibody a swine multi-link IgG1 anti-goat/mouse/rabbit conjugated with biotin and diluted 1:50 was

employed, followed by streptavidin–horseradish peroxidase (DAKO, Denmark). Positive cells were visualized with 3,3-diaminobenzidine hydrochloride and the nuclei were counterstained with haematoxylin.

Scoring

Two independent observers evaluated the sections using a light microscopy Leica DM LS (Leica Microsystems; Wetzlar, Germany). In case of HRG, we analyzed the staining associated to malignant cells and the surrounding stromal cells (fibroblasts). Tumours were considered positive for the stromal reaction when 10% or more stained fibroblasts were observed. In this case the imprints were excluded for being unreliable. In the malignant population we considered intensity (+ or ++) and frequency: (a) 0 cells; (b) 1–10% cells; (c) >10–50% cells; and (d) >50% of the cells being positive. The frequency and intensity were added to regroup the variable into three categories: (1) no reaction; (2) low reaction (1–10%/+/++ or >10–50%/+); (3) strong reaction (>10–50%/++ or staining in >50%/+/++).

For Akt-1 and pAkt, the tumours were considered positive, independently of the frequency, when the brown colour observed in the cytoplasm of the cells was strong and clearly different from that of the negative control. For Bcl-2, a cut-off point of $\geq 10\%$ was considered on the base of previous studies (Hellemans *et al*, 1995; Elledge *et al*, 1997).

Peptide neutralization assay

Blockade with synthetic peptides tested the specificity of the polyclonal antibodies. The highest working dilution for the antibodies was established as $2 \mu\text{g ml}^{-1}$ in case of pAkt and $0.5 \mu\text{g ml}^{-1}$ in case of HRG. To be neutralized, the antibodies were pre-incubated overnight at 4°C with five and 10 times more peptide (for pAkt and HRG respectively) in a total volume of $100 \mu\text{l}$ and centrifuged at 10 000 g. Supernatants were applied to the sections.

Statistics

The relationships between different variables were assessed by the Chi-square test or Chi-square test for trend, when required. The role of each variable (univariate analysis) or their joint effect (multivariate analysis) was evaluated with Cox's proportional hazard regression. The multiple sample test, which is a generalization of Gehan's generalized Wilcoxon test, was also used to test the significance in the survival analysis. All the procedures are comprised in the statistical package 'Statistica' (Statsoft, inc 1999 Statistica for Windows). The criterion for statistical significance was $P < 0.05$.

RESULTS

Association of Akt-1 and pAkt with other variables

The pattern of staining for Akt-1 is shown in Figure 1A. The protein was expressed in 46% of the tumours without significant correlation with any prognostic factor. On the other hand, pAkt, positive in 54% of the cases (Figure 1B), was positively correlated with the presence of HRG-expressing fibroblasts ($P=0.017$) and inversely to the SPF ($P=0.001$). No association was seen with nodal status, tumour size, ER, PgR, Bcl-2 or *erbB-2* (Table 1). A moderate correlation, although statistically significant ($P=0.04$), was found between Akt-1 and pAkt staining. Besides, HRG, observed in malignant cells, was negatively associated with lymph node status ($P=0.005$) and with ER ($P=0.026$). The controls consisting of peptide-blocked antibodies were negative in all cases (result not shown).




Figure 1 Representative immunostaining of Akt-1 (A) (200 ×) and pAkt (B) (400 ×), note the arrowheads indicating positive staining in the cytoplasm of malignant cells.

pAkt and other variables in relation to distant recurrence-free survival

In univariate analysis neither HRG nor Akt-1 had prognostic value, while pAkt positivity predicted a higher risk of developing metastasis with borderline significance (RR=2.4, 95% CI, 1.0–6.2) (see Figure 2A). Multivariate analysis, including pAkt and traditional prognostic factors, indicated that pAkt was an independent predictor of distant recurrence (Table 2). The risk in the pAkt+ group was higher (5.4) compared to the pAkt– group; (P=0.004). Besides, the risk also increased significantly for the lymphnode positive patients (P=0.0008) and for those with high SPF (P=0.01).

The possible phenotypes of pAkt in combination with SPF are shown in Figure 2B. Patients with low SPF and pAkt negative tumour had a 6 year survival rate of 93% in comparison with 47% for those with high SPF and pAkt positive phenotype. The distant recurrence-free survival in relation to pAkt and nodal status is shown in Figure 2C. All patients in the double negative group (node-/pAkt-) remained alive after 6 years of follow-up while in the node+/pAkt+ group the distant recurrence-free survival rate fell to 59%.

DISCUSSION

As far as we know this is the first immunohistochemical study analyzing the expression and activation of Akt in breast tumours in relation to other clinico-pathological variables and survival.




Figure 2 (A) Kaplan–Meier curves comparing survival among pAkt negative patients in comparison with pAkt positive group (P=0.07 by Cox proportional hazard model and P=0.03 by Gehan’s generalized Wilcoxon test). (B) pAkt/SPF subgroups. The combined variable was scored as: 0 (SPF-/pAkt-); 1 (SPF+/pAkt-); 2 (SPF-/pAkt+); 3 (SPF+/pAkt+). According to this order, the risk of developing distant recurrence increased gradually with a rate ratio of 1.8 (Cox proportional hazard regression, P=0.017). Distant recurrence-free survival rates at 6 years were of 93, 88, 69 and 47% respectively for each subgroup. (C) Kaplan–Meier curves based on pAkt and nodal status. The combined variable was scored as: 0 (node-/pAkt-); 1 (node-/pAkt+); 2 (node+/pAkt-); 3 (node+/pAkt+). According to this order, the risk of developing distant recurrence increased gradually with a rate ratio of 2.5 (Cox proportional hazard regression P=0.001). Distant recurrence-free survival rates at 6 years were 100, 85, 81 and 59% respectively for each subgroup. In the lymph node negative group there were two recurrences; both belonged to pAkt+ subgroup.

Table 1 Akt-1 and pAkt in relation to other clinical data and tumour characteristics

	Akt-1 – n (%)	Akt-1+ n (%)	Significance	pAkt – n (%)	pAkt+ n (%)	Significance
Nodal status						
–	20 (57)	15 (43)	P=0.60	18 (51)	17 (49)	P=0.43
+	30 (52)	28 (48)		25 (43)	33 (57)	
Tumour size						
< 20 mm	25 (59)	17 (40)	P=0.30	17 (59)	25 (41)	P=0.30
≥ 20 mm	25 (49)	26 (51)		26 (51)	25 (49)	
ER						
–	11 (50)	11 (50)	P=0.70	13 (59)	9 (41)	P=0.16
+	39 (55)	32 (45)		30 (42)	41 (58)	
PgR						
–	4 (57)	3 (43)	P=0.85	4 (57)	3 (43)	P=0.54
+	46 (53)	40 (47)		39 (45)	47 (55)	
SPF ^a						
< 10%	20 (44)	25 (56)	P=0.08	15 (33)	30 (67)	P=0.001
≥ 10%	23 (64)	13 (36)		25 (69)	11 (31)	
erbB-2						
FI < 2.0	48 (55)	39 (45)	P=0.30	40 (46)	47 (54)	P=0.80
FI ≥ 2.0	2 (33)	4 (67)		3 (50)	3 (50)	
Bcl-2						
–	24 (62)	15 (38)	P=0.20	17 (44)	22 (56)	P=0.60
+	26 (48)	28 (52)		26 (48)	28 (52)	
HRGβ1 malignant cells ^b						
No	17 (59)	12 (41)	P=0.90	16 (55)	13 (45)	P=0.43
Low	17 (44)	22 (56)		15 (38)	24 (62)	
High	13 (59)	9 (41)		10 (45)	12 (55)	
HRGβ1 host cells ^c						
< 10%	31 (60)	21 (40)	P=0.15	28 (78)	8 (22)	P=0.017
≥ 10%	13 (43)	17 (57)		24 (52)	22 (48)	

^a, ^b, ^cData from 12, 3 and 11 patients respectively is missing.

Table 2 Multivariate Cox proportional hazard regression to determine the predictive value of different variables in relation to distant recurrence. Data for all of the patients was available in 81 cases

	Rate ratio (95% CI)	Significance
Nodal status		
–	1.0	P=0.008
+	13.9 (2.9–63.1)	
Tumour size		
< 20 mm	1.0	P=0.37
≥ 20 mm	1.5 (0.6–3.7)	
ER		
–	1.0	P=0.37
+	0.58 (0.2–1.9)	
PgR		
–	1.0	P=0.93
+	0.9 (0.2–5.4)	
SPF		
< 10%	1.0	P=0.01
≥ 10%	3.9 (1.4–10.7)	
pAkt		
–	1.0	P=0.004
+	5.4 (1.7–17.1)	

We aimed to examine whether this protein, found *in vitro* to play a prominent role in oncogenesis (Kandel and Hay, 1999) and possibly in tamoxifen resistance (Campbell *et al*, 2001), showed the same significance in clinical material.

In this study, Akt-1 was considered positive in 46% of the tumours but it was not associated with any other prognostic marker. The variable did not provide any new information regard-

ing the survival of the patients. Despite a positive correlation between Akt-1 and the activated protein, some Akt-1 negative cases resulted as pAkt positive. This paradox may be explained by either different sensitivity of the antibodies or by crossreactivity of the phospho-Akt-1 (ser473) antibody with another activated isoform present in the tumour, like Akt-2 or Akt-3. Otherwise, the pattern of staining with both antibodies was similar, being the phosphorylated protein localized to some extent to the cell membrane and mainly observed in the cytoplasm of the malignant cells. Albeit the activation of Akt is generally associated with its translocation from the cytosol to the plasma membrane by virtue of its pleckstrin homology (PH) domain (Andjelkovic *et al*, 1997), it is possible for Akt lacking a PH domain to be activated without being localized to this cell compartment (Sable *et al*, 1998).

As in case of Akt-1, we could not find any significant association of pAkt with nodal status, tumour size, ER, PgR or Bcl-2 but we did find a strong negative association with SPF. Since the activation of Akt promotes cell cycle progression by modulating the expression (Brennan *et al*, 1997; Muise-Helmericks *et al*, 1998) and stabilization of cyclin D1 (Graff *et al*, 2000) and the SPF is an indicator of the proliferative state of the cells, the negative association between pAkt and SPF was unexpected. Nevertheless, an increase in cyclin D1 does not always lead to cell cycle progression (Hiyama *et al*, 1997; Mitsuuchi *et al*, 2000), and in some cases the expression of cyclin D1 has been associated with low proliferative rate in clinical material (Nielsen *et al*, 1999). Furthermore, the survival analysis indicated that patients in the pAkt positive group tended to have a higher risk to develop distant recurrence compared to the negative group, and the multivariate analysis showed that pAkt was an independent prognostic factor in addition to nodal status and SPF. The analysis of the interaction between pAkt and SPF revealed that a low SPF was a favourable feature only if the tumour

was in addition pAkt negative. This suggests that pAkt could be indicative of distant relapses in spite of a low proliferative state of the tumour, probably by promoting cell survival rather than cell proliferation.

In a previous report, including 20 adenocarcinomas, a significant association was found between the expression of *erbB-2* and pAkt (Zhou *et al*, 2000). In the present study we found no significant association of *erbB-2* with Akt-1 or with pAkt. We consider that our study could be undersized to detect significant differences, since only 7% of the tumours overexpressed the receptor ($n=6$) as expected in a sample conformed mostly by ER or PgR positive tumours. Therefore a larger material might help to confirm this relationship but also it may be interesting to address this question in the context of other EGF family members such as *erbB-3*, 4 and EGFR.

In this study we also explored the ligand HRG. The protein can be present in the cytoplasm of both malignant and stromal cells. While in a previous report, the host-derived HRG correlated with aggressive clinical behaviour (Visscher *et al*, 1997) we did not find the same result in our study. However we found a positive correlation between host-derived HRG and pAkt. It is known that the breast stroma plays an important role in breast epithelial growth and differentiation. Besides, tumour-associated fibroblasts have been found to confer morphogenic and mitogenic induction of epithelial cells (Shekhar *et al*, 2001) and to induce acceleration of epithelial tumour growth *in vivo* (Camps *et al*, 1990) supporting the role of host cells as source of paracrine signals that may not only affect cell growth but also turn on survival pathways, like Akt.

On the other hand, in those tumours where HRG was found in the malignant cells the patients less often showed evidence of lymphonodal spread in line with the results of Bacus *et al* (1994). The negative association found with ER status still could implicate this factor with an aggressive phenotype, although the

risk to develop distant metastasis was not higher among the patients with high expression of HRG. A possible interaction with nodal status is not excluded since among the node positive patients the recurrence rate tended to be higher in cases of high HRG expression (result not shown). Nevertheless the role of HRG *in vivo* remains to be explained. This factor has been associated *in vitro* with induction of cell proliferation (Holmes *et al*, 1992; Aguilar *et al*, 1999), invasion (Hijazi *et al*, 2000), apoptosis (Daly *et al*, 1997), differentiation (Peles *et al*, 1992; Bacus *et al*, 1993) and inhibition of cell proliferation (Hamburger and Yoo, 1997; Xu *et al*, 1997).

We conclude that the activation of Akt could be a factor to consider together with S-phase fraction and nodal status in predicting distant relapses of breast cancer. However it remains to be elucidated which isoform plays the principal role. The shorter disease-free survival associated with the pAkt positive phenotype in this series of endocrine treated patients, may indicate a link between this pathway and treatment failure but further studies based on randomized trials are needed to validate this hypothesis.

ACKNOWLEDGEMENTS

This work was supported by grants from the Swedish Cancer Society and the Research Council of Southeast Sweden.

Members of the Southeast Sweden Breast Cancer Group LG Arnesson, A Malmström, B Nordenskjöld, K Nordenskjöld, (Linköping), H Bång (Motala), A Ch Källström (Norrköping), E Einarsson (Eksjö), B Norberg (Jönköping), P Skoog (Värnamo), Å Henning (Oskarshamn), M Sundquist (Kalmar), G Tejler (Västervik).

REFERENCES

- Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ (1999) Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. *Oncogene* **18**: 6050–6062
- Ahmad S, Singh N, Glazer RI (1999) Role of AKT1 in 17 β -estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. *Biochem Pharmacol* **58**: 425–430
- Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, Taguchi T, Testa JR, Tschlis PN (1993) The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. *Oncogene* **8**: 1957–1963
- Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA (1997) Role of translocation in the activation and function of protein kinase B. *J Biol Chem* **272**: 31515–31524
- Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, Wen D, Sela M, Yarden Y (1993) Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. *Cancer Res* **53**: 5251–5261
- Bacus SS, Zelnick CR, Plowman G, Yarden Y (1994) Expression of the *erbB-2* family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. *Am J Clin Pathol* **102**: S13–S24
- Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Panici BP, Mancuso S, Neri G, Testa JR (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. *Int J Cancer* **64**: 280–285
- Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA (1997) Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. *Immunity* **7**: 679–689
- Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. *J Biol Chem* **276**: 9817–9824
- Camps JL, Chang SM, Hsu TC, Freeman MR, Hong SJ, Zhou HE, von Eschenbach AC, Chung LW (1990) Fibroblast-mediated acceleration of human epithelial tumor growth *in vivo*. *Proc Natl Acad Sci USA* **87**: 75–79
- Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci USA* **93**: 3636–3641
- Clarke R, Leonessa F, Welch JN, Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. *Pharmacol Rev* **53**: 25–71
- Coffer PJ, Jin J, Woodgett JR (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. *Biochem J* **335**: 1–13
- Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE (1997) Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. *Cancer Res* **57**: 3804–3811
- Duan C, Liimatta MB, Bottum OL (1999) Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. *J Biol Chem* **274**: 37147–37153
- Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK (1997) bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. *J Clin Oncol* **15**: 1916–1922

- Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbailu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. *J Biol Chem* **275**: 24500–24505
- Hamburger AW, Yoo JY (1997) Phosphatidylinositol 3-kinase mediates heregulin-induced growth inhibition in human epithelial cells. *Anticancer Res* **17**: 2197–2200
- Hellems P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E (1995) Prognostic value of bcl-2 expression in invasive breast cancer. *Br J Cancer* **72**: 354–360
- Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R (2000) Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. *Int J Oncol* **17**: 629–641
- Hiyama H, Iavarone A, LaBaer J, Reeves SA (1997) Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. *Oncogene* **14**: 2533–2542
- Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang JW, Wood WI, Goeddel DV, Vandlen RL (1992) Identification of heregulin, a specific activator of p185erbB2. *Science* **256**: 1205–1210
- Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, Ethier SP (2000) ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. *Br J Cancer* **82**: 666–674
- Imai A, Tamaya T (2000) GnRH receptor and apoptotic signaling. *Vitam Horm* **59**: 1–33
- Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. *Exp Cell Res* **253**: 210–229
- Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A (1996) Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. *Mol Cell Biol* **16**: 5905–5914
- Liu W, Li J, Roth RA (1999) Heregulin regulation of Akt/protein kinase B in breast cancer cells. *Biochem Biophys Res Commun* **261**: 897–903
- MacGregor JJ, Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. *Pharmacol Rev* **50**: 151–196
- Michaud LB, Buzdar AU (2000) Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. *Drugs Aging* **16**: 261–271
- Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR (2000) The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. *Cancer Res* **60**: 5390–5394
- Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tschlis PN, Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. *J Biol Chem* **273**: 29864–29872
- Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G (1999) G1-S transition defects occur in most breast cancers and predict outcome. *Breast Cancer Res Treat* **56**: 105–112
- Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H (2000) Akt/Protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. *J Biol Chem* **275**: 30934–30942
- Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y (1992) Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. *Cell* **69**: 205–216
- Perry RR, Kang Y, Greaves B (1995) Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. *Ann Surg Oncol* **2**: 238–245
- Ram TG, Ethier SP (1996) Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. *Cell Growth Differ* **7**: 551–561
- Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. *Mol Carcinog* **21**: 81–86
- Sable CL, Filippa N, Filloux C, Hemmings BA, Van Obberghen E (1998) Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. *J Biol Chem* **273**: 29600–29606
- Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L (2001) Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. *Cancer Res* **61**: 1320–1326
- Staal SP (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. *Proc Natl Acad Sci USA* **84**: 5034–5037
- Stål O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B (1992) Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The South-East Sweden Breast Cancer Group. *Int J Cancer* **51**: 28–33
- Stål O, Sullivan S, Sun XF, Wingren S, Nordenskjöld B (1994) Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. *Cytometry* **16**: 160–168
- Tan M, Grijalva R, Yu D (1999) Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. *Cancer Res* **59**: 1620–1625
- Visscher DW, Sarkar FH, Kasunic TC, Reddy KB (1997) Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. *Breast Cancer Res Treat* **45**: 75–80
- Xu FJ, Stack S, Boyer C, O'Brian K, Whitaker R, Mills GB, Yu YH, Bast Jr RC (1997) Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. *Clin Cancer Res* **3**: 1629–1634
- Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. *J Biol Chem* **275**: 8027–8031